Breaks Categories: News

FridayDec 03, 2021 9:39 am

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Upcoming Sequire Clean Tech & EV Virtual Conference

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, will be hosting the first-ever Sequire Clean Tech & EV Conference. The investor event will be held on Dec. 6, 2021. This premier gathering is designed to feature a variety of companies, including those in the EV, energy and power, materials and chemicals, and food and agriculture industries. Green energy and sustainability are becoming top priorities in today’s world, and this inaugural gathering is designed to create an invaluable opportunity for premier innovators in the clean-tech space to…

Continue Reading

FridayDec 03, 2021 9:30 am

NetworkNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Lucid-MS Featured in InvestmentPitch Video, CEO to Present at H.C. Wainwright Psychedelics Virtual Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on over a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. FSD Pharma has released a video…

Continue Reading

ThursdayDec 02, 2021 12:04 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to CNS Pharmaceuticals, Berubicin is the first anthracycline that appears to cross the blood-brain barrier; the substance is being assessed in a global study designed to evaluate efficacy and safety in the treatment of recurrent glioblastoma multiforme (“GBM”). The adaptive, multicenter, open-label, randomized and controlled study…

Continue Reading

ThursdayDec 02, 2021 11:32 am

NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

Continue Reading

ThursdayDec 02, 2021 10:30 am

NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The…

Continue Reading

ThursdayDec 02, 2021 10:01 am

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Continue Reading

ThursdayDec 02, 2021 9:27 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare Conference. The conference, which is slated for Dec. 8, 2021, will include a presentation by Cybin CEO Doug Drysdale. According to the announcement, Drysdale’s presentation is scheduled to start at 3:30 p.m. ET. Following the presentation, interested viewers can view an archived version of the webcast on Cybin’s investor relations website. Cybin is working to create safe and effective therapeutics for patients to address a multitude of mental health issues. To view the…

Continue Reading

ThursdayDec 02, 2021 8:30 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin, which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra,…

Continue Reading

WednesdayDec 01, 2021 2:39 pm

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

Continue Reading

WednesdayDec 01, 2021 2:28 pm

NetworkNewsBreaks – DeepMarkit Corp. (TSX.V: MKT) (OTC: MKTDF) Announces LOI for Acquisition of First Carbon Corp., Concurrent Private Placement

DeepMarkit (TSX.V: MKT) (OTC: MKTDF) recently announced its entry into a non-binding letter of intent (“LOI”) to acquire all of the issued and outstanding shares of First Carbon Corp. (“FCC”). The LOI sets forth the general terms and conditions of the acquisition, pursuant to which FCC shareholders will receive an aggregate of approximately 15,000,000 common shares of DeepMarkit (“common shares”), each issued at a deemed price of $0.50, for deemed consideration of approximately $7,500,000 (the “acquisition”). In addition, DeepMarkit announced a non-brokered private placement. Under the private placement, subject to acceptance by the TSX Venture Exchange, DeepMarkit intends to issue,…

Continue Reading